Cravath Publishes Summer 2026 Issue of Alumni Journal
Daniel Slifkin retired from Cravath’s Litigation Department in June 2026. During his 35 years at the Firm, Mr. Slifkin handled a range of complex, business‑critical litigation for his clients, including trying significant cases in courts nationwide and in domestic and international arbitrations.
Mr. Slifkin’s practice focused on securities and derivative matters, antitrust and general commercial litigation, and bankruptcy proceedings. He was selected as a Fellow of the American College of Trial Lawyers, and is among the few litigators to have taken a securities fraud class action through jury verdict. Mr. Slifkin also represented clients in regulatory investigations by the Department of Justice, Securities and Exchange Commission and European Union.
Mr. Slifkin was born in London, England. He received a B.A., with first class honors, from the University of Oxford in 1987; a B.C.L., with first class honors, from the University of Oxford in 1988; and a J.D. magna cum laude from Harvard Law School in 1991, where he was an editor of the Harvard Law Review and a Sears Prize winner.
Mr. Slifkin joined Cravath in 1991 and was elected a partner in 1997. He served as Head of the Litigation Department from September 2016 to February 2021.
Mr. Slifkin’s practice focused on securities and derivative matters, antitrust and general commercial litigation, and bankruptcy proceedings. He was selected as a Fellow of the American College of Trial Lawyers, and is among the few litigators to have taken a securities fraud class action through jury verdict. Mr. Slifkin also represented clients in regulatory investigations by the Department of Justice, Securities and Exchange Commission and European Union.
Mr. Slifkin was born in London, England. He received a B.A., with first class honors, from the University of Oxford in 1987; a B.C.L., with first class honors, from the University of Oxford in 1988; and a J.D. magna cum laude from Harvard Law School in 1991, where he was an editor of the Harvard Law Review and a Sears Prize winner.
Mr. Slifkin joined Cravath in 1991 and was elected a partner in 1997. He served as Head of the Litigation Department from September 2016 to February 2021.
Education
-
J.D., 1991, Harvard Law SchoolSears Prize, magna cum laude
-
B.C.L., 1988, University of OxfordFirst Class Honors
-
B.A., 1987, University of OxfordFirst Class Honors
Deals & Cases
July 21, 2025
ZimVie’s Acquisition by ARCHIMED
On July 21, 2025, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental implant market, announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries. Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately $730 million. Cravath is representing ZimVie in connection with the transaction.
Deals & Cases
November 15, 2023
Robinhood Defeats Certification of Proposed Class Asserting Securities Claims in Sprawling “Meme Stock” Litigation
On November 13, 2023, the U.S. District Court for the Southern District of Florida denied plaintiffs’ motion to certify a class asserting market manipulation claims under the federal securities laws against Cravath clients Robinhood Markets, Inc., Robinhood Financial LLC and Robinhood Securities, LLC (together, “Robinhood”).
Deals & Cases
February 03, 2012
Shareholder Claims Against Vivendi Dismissed
On January 27, 2012, Judge Richard J. Holwell of the Southern District of New York dismissed all claims against Vivendi, S.A. brought by individual plaintiffs who purchased Vivendi ordinary shares on foreign exchanges. In his opinion, Judge Holwell cited the June 2010 U.S. Supreme Court decision in Morrison v. National Australia Bank Ltd, which altered then-prevailing Second Circuit law concerning the scope of Section 10(b) of the Securities Exchange Act of 1934 (and Rule 10b-5 promulgated thereunder) by holding that Section 10(b) does not apply extraterritorially. The individual plaintiffs had alleged that Vivendi misled shareholders about its financial condition between 2000 and 2002. The same Southern District of New York court previously applied Morrison to the Vivendi class action litigation in a decision dated February 17, 2011, dismissing the claims of the class action plaintiffs who purchased Vivendi ordinary shares. Cravath has represented Vivendi in various securities litigation since 2002.
Activities
March 14, 2025
Daniel Slifkin Admitted to American College of Trial Lawyers
On March 8, 2025, Cravath partner Daniel Slifkin became a Fellow of the American College of Trial Lawyers, one of the premier legal associations in North America. The induction ceremony took place during the 2025 Spring Meeting of the College in Maui, Hawaii.
Activities
October 09, 2024
Benchmark Litigation Ranks Three Cravath Partners Among the 2025 Top 100 Trial Lawyers
The 2025 edition of Benchmark Litigation named Cravath partners Daniel Slifkin, Gary A. Bornstein and Kevin J. Orsini to its list of the “Top 100 Trial Lawyers,” which consists of “partners who have been venerated by peers and clients as being the best in breed at the nuanced practice of trial law.” This is the fifth year in which Daniel and Kevin have been recognized and the fourth year in which Gary has been named to the list.
Daniel Slifkin retired from Cravath’s Litigation Department in June 2026. During his 35 years at the Firm, Mr. Slifkin handled a range of complex, business‑critical litigation for his clients, including trying significant cases in courts nationwide and in domestic and international arbitrations.
Mr. Slifkin’s practice focused on securities and derivative matters, antitrust and general commercial litigation, and bankruptcy proceedings. He was selected as a Fellow of the American College of Trial Lawyers, and is among the few litigators to have taken a securities fraud class action through jury verdict. Mr. Slifkin also represented clients in regulatory investigations by the Department of Justice, Securities and Exchange Commission and European Union.
Mr. Slifkin was born in London, England. He received a B.A., with first class honors, from the University of Oxford in 1987; a B.C.L., with first class honors, from the University of Oxford in 1988; and a J.D. magna cum laude from Harvard Law School in 1991, where he was an editor of the Harvard Law Review and a Sears Prize winner.
Mr. Slifkin joined Cravath in 1991 and was elected a partner in 1997. He served as Head of the Litigation Department from September 2016 to February 2021.
Mr. Slifkin’s practice focused on securities and derivative matters, antitrust and general commercial litigation, and bankruptcy proceedings. He was selected as a Fellow of the American College of Trial Lawyers, and is among the few litigators to have taken a securities fraud class action through jury verdict. Mr. Slifkin also represented clients in regulatory investigations by the Department of Justice, Securities and Exchange Commission and European Union.
Mr. Slifkin was born in London, England. He received a B.A., with first class honors, from the University of Oxford in 1987; a B.C.L., with first class honors, from the University of Oxford in 1988; and a J.D. magna cum laude from Harvard Law School in 1991, where he was an editor of the Harvard Law Review and a Sears Prize winner.
Mr. Slifkin joined Cravath in 1991 and was elected a partner in 1997. He served as Head of the Litigation Department from September 2016 to February 2021.
Education
-
J.D., 1991, Harvard Law SchoolSears Prize, magna cum laude
-
B.C.L., 1988, University of OxfordFirst Class Honors
-
B.A., 1987, University of OxfordFirst Class Honors
Deals & Cases
July 21, 2025
ZimVie’s Acquisition by ARCHIMED
On July 21, 2025, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental implant market, announced their entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”), an investment firm focused exclusively on healthcare industries. Under the terms of the merger agreement, ZimVie stockholders will receive $19.00 in cash for each share of ZimVie common stock outstanding at the closing of the transaction, corresponding to an enterprise value of approximately $730 million. Cravath is representing ZimVie in connection with the transaction.
Deals & Cases
November 15, 2023
Robinhood Defeats Certification of Proposed Class Asserting Securities Claims in Sprawling “Meme Stock” Litigation
On November 13, 2023, the U.S. District Court for the Southern District of Florida denied plaintiffs’ motion to certify a class asserting market manipulation claims under the federal securities laws against Cravath clients Robinhood Markets, Inc., Robinhood Financial LLC and Robinhood Securities, LLC (together, “Robinhood”).
Deals & Cases
February 03, 2012
Shareholder Claims Against Vivendi Dismissed
On January 27, 2012, Judge Richard J. Holwell of the Southern District of New York dismissed all claims against Vivendi, S.A. brought by individual plaintiffs who purchased Vivendi ordinary shares on foreign exchanges. In his opinion, Judge Holwell cited the June 2010 U.S. Supreme Court decision in Morrison v. National Australia Bank Ltd, which altered then-prevailing Second Circuit law concerning the scope of Section 10(b) of the Securities Exchange Act of 1934 (and Rule 10b-5 promulgated thereunder) by holding that Section 10(b) does not apply extraterritorially. The individual plaintiffs had alleged that Vivendi misled shareholders about its financial condition between 2000 and 2002. The same Southern District of New York court previously applied Morrison to the Vivendi class action litigation in a decision dated February 17, 2011, dismissing the claims of the class action plaintiffs who purchased Vivendi ordinary shares. Cravath has represented Vivendi in various securities litigation since 2002.
Activities
March 14, 2025
Daniel Slifkin Admitted to American College of Trial Lawyers
On March 8, 2025, Cravath partner Daniel Slifkin became a Fellow of the American College of Trial Lawyers, one of the premier legal associations in North America. The induction ceremony took place during the 2025 Spring Meeting of the College in Maui, Hawaii.
Activities
October 09, 2024
Benchmark Litigation Ranks Three Cravath Partners Among the 2025 Top 100 Trial Lawyers
The 2025 edition of Benchmark Litigation named Cravath partners Daniel Slifkin, Gary A. Bornstein and Kevin J. Orsini to its list of the “Top 100 Trial Lawyers,” which consists of “partners who have been venerated by peers and clients as being the best in breed at the nuanced practice of trial law.” This is the fifth year in which Daniel and Kevin have been recognized and the fourth year in which Gary has been named to the list.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.